In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.
The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.
OncoPlex operates a CAP-accredited and CLIA-certified laboratory and provides mass spectrometry-based tumor profiling services.
The funding will be used to further expand the company's clinical testing products and services in the US and abroad.
Using a self-similar chain-based device combined with Raman spectroscopy, they were able to detect the BRCA1 missense mutation M1775R at picomolar levels.
The investment bank has a $4 price target on Vermillion's stock and noted the firm's OVA2 test, a change to its relationship with Quest, and new management.
The proteomics-based diagnostics firm will use proceeds from the financing for continued commercial development, prospective clinical trials, and other purposes.
The core will serve as a center for receiving, qualifying, processing, and distributing biospecimens to the Clinical Proteomic Tumor Analysis Consortium.
Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
The reverse stock split was done in order for BG Medicine to remain listed on Nasdaq, which had warned the firm in September of possible delisting action.
The company repurchased a total of 860,595 shares of its common stock, with the price based on a simple average of closing prices for a trailing 60-day period.
In the UK it initially will be offered through private clinics on a "self-pay" basis, while in the US it will be sold as a laboratory-developed test through Abcodia's CLIA lab.
The tests combine the company's second-generation proteomic ovarian cancer test OVA2 with patient ultrasound results and symptom data.
Researchers working onbreast, colorectal, and ovarian cancer highlighted their work, making the case for proteogenomic approaches to cancer research.
Product revenues, comprised of OVA1 sales, were also flat at $1.5 million, as were licensing revenues at $113,000.
The company cited as likely applications development of tests for guiding therapy in late-stage patients and support of drug development efforts.
As it tries to kick-start stalled revenue growth, the company must work to convince doctors the test offers benefits beyond standard of care.
The MRM-MS-based method combines use of conventional stable isotope-labeled peptide standards with a series of endogenous protein standards.
What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.
A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.